Pfizer (PFE) – Hedged Covered Call Income CampaignAfter Pfizer’s return to price levels closer to its pre-COVID range, I personally believe the stock is undervalued relative to its current earnings profile and long-term potential. This view is also influenced by Pfizer’s recent acquisition of Metsera, which brings a pipeline of obesity and cardiometabolic candidates — including GLP-1 receptor agonists, an amylin analog, and other metabolic therapies.
Whether this pipeline ultimately succeeds is uncertain, but in my opinion, it meaningfully strengthens Pfizer’s long-term outlook.
This campaign is structured as a hedged, conservative covered-call income strategy, combining downside protection with steady premium generation.
Current Position
1. Long Shares: 700 shares @ $24.94
2. Protective Long Puts: 7 puts @ $19 strike (exp. 1/16/26), Cost: $35 total
Because PFE’s implied volatility is relatively low, these long-dated puts provide very inexpensive downside protection, defining maximum risk and allowing me to run covered calls with confidence. This is my preferred way to reduce tail risk on slower-moving stocks.
Covered Calls (Income)
I am selling near-term calls at the $25 strike and rolling as needed.
Call Activity So Far:
A. Initial Sell
• 7 contracts @ $0.11 → $77 total
• Expiration: 11/07/2025
B. Roll #1
• 7 contracts @ $0.15 → $105 total
• Expiration: 11/11/2025
C. Roll #2
• 7 contracts @ $0.15 → $105 total
• Expiration: 11/17/2025
Dividend Component:
Pfizer’s dividend provides a third income source that complements the weekly call premiums. With 700 shares, my next scheduled dividend payment is $310.89 on December 1st. this is nearly a 7% yield.
Dividends enhance this strategy by:
1. Reducing effective cost basis over time
2. Providing a reliable quarterly income
3. Making slower-moving stocks like PFE well-suited for hedged income trading
4. Smoothing returns even during flat price periods
This is one reason I favor PFE for long-term defensive income strategies.
These rolls follow my usual “roll out only” approach — extending time value without paying unnecessary extrinsic premium. This keeps weekly income stable while managing assignment risk.
PFIZER
Pfizer stock exploded as expected from weekly demandPfizer just did it again!
After weeks of sleeping inside that weekly demand imbalance, the pharmaceutical giant exploded — exactly as expected from our supply and demand forecast. Price has already rallied more than 7%, proving once again how powerful these imbalances can be when you learn to read them properly.
Pfizer stock exploded as expected from weekly demand strong imbalance. The pharmaceutical company has already rallied 7% rally from the imbalance originated at $24.39. It's all about supply and demand.
Pfizer’s $PFE Demand Zone — Ready to Explode?Hey traders, it’s Alfonso Moreno from Set and Forget! Today, I’m diving into one of the most famous pharmaceutical giants on the planet — Pfizer. Yes, that Pfizer. Love them or hate them, the chart doesn’t lie. The weekly timeframe just gave us a brand-new demand imbalance, and it’s looking ready to roar. Let’s break it down and see if Pfizer could be preparing for a bullish comeback.
The New Weekly Demand Imbalance
We’ve got a fresh weekly demand imbalance trading between $24.39 and $23.58, and it’s already gained control. This is the largest bullish candlestick in months — a clear reaction showing professional buying pressure stepping in after months of drifting lower.
The beauty of this setup?
The risk is under $1, which makes it a tight and well-defined imbalance — a pocket of price where institutions previously decided to buy aggressively.
Pfizer (PFE): Undervalued Pharma Giant Amid #Economy Resilience?Pfizer (PFE): Undervalued Pharma Giant Amid #Economy Resilience? $28.90 in Sight? 📈
At $24.04 (+0.04%), PFE offers a compelling entry with its low P/E of 12.72 and robust 7.15% dividend yield, trading well below analyst targets of $28.90 (20% upside potential)—could resilient economic forecasts boost healthcare demand and spark a rally? 🚀
**Fundamental Analysis**
Pfizer boasts EPS (TTM) of $1.89 and revenue (TTM) of $63.83B, with a PEG ratio of 0.96 signaling undervaluation relative to growth prospects; DCF models suggest intrinsic value above current levels given strong cash flows of $16.02B, though patent expirations weigh on margins.
- **Positive:** High dividend yield supports income-focused portfolios; diversified pipeline in oncology and vaccines drives long-term revenue stability.
- **Negative:** Elevated enterprise value/EBITDA at 9.15 reflects debt from acquisitions; regulatory hurdles could delay new approvals.
**SWOT Analysis**
**Strengths:** Broad product portfolio and global reach; strong R&D investment.
**Weaknesses:** High debt levels post-acquisitions; dependency on blockbuster drugs.
**Opportunities:** Expanding into emerging markets amid economic growth; AI-driven drug discovery partnerships.
**Threats:** Generic competition; geopolitical tensions impacting supply chains.
**Technical Analysis**
Chart shows consolidation in a tight range with emerging bullish momentum. Price: $24.04, VWAP $24.10.
Key indicators:
- RSI: 45 (neutral, room for upside without overbought risk).
- MACD: Positive crossover signaling building momentum.
- Moving Averages: 50-day at $25 (potential breakout level), 200-day at $26 (long-term trendline).
Support/Resistance: Support at $23, resistance at $25. Patterns/Momentum: Ascending triangle forming, favoring bulls on volume increase. 📈 Bullish | ⚠️ Bearish.
**Scenarios and Risk Management**
- **Bullish:** Entry above $25 on volume, DCA in dips to average down for 20% upside to targets.
- **Bearish:** Drop below $23 on weak earnings, exit positions.
- **Neutral:** Sideways trade between support/resistance amid macro waits.
Risk Tips: Set stops at 5% below entry, limit position to 2-3% of portfolio, diversify across sectors, and apply DCA to mitigate volatility. ⚠️
**Conclusion/Outlook**
Bullish bias if economic resilience sustains healthcare spend. Watch Fed remarks. Fits value theme with #Economy upside. Take? Comment!
Pfizer and Pharma Stocks Rise After Trump DecisionPfizer Inc. (PFE) and Other Pharmaceutical Stocks Rise Following Trump’s Decision
According to media reports, US President Donald Trump launched a website allowing Americans to purchase medicines directly. He announced that Pfizer would offer some of its drugs on this platform and introduce new medicines to the US market at reduced prices. Trump added that his administration is working with other companies, including Eli Lilly, to reach “similar agreements.”
Reports state that Pfizer’s deal with the Trump administration will enable patients to receive significant discounts. In return, the company will receive a three-year exemption from any tariffs.
The news pushed pharmaceutical stocks to the top of yesterday’s gainers list:
→ Pfizer Inc. (PFE) rose by 6.8%
→ Merck & Co Inc. (MRK) rose by 6.8%
→ Eli Lilly and Co. (LLY) rose by 5.0%
Technical analysis of the PFE chart
The chart indicates that:
→ In the long term, PFE’s share price remains in a bearish trend, highlighted by the descending orange channel.
→ However, in April the stock reached its lowest level in nearly 13 years, after which the price began showing an upward trajectory, forming higher highs and higher lows within the ascending blue channel.
A strong fundamental driver yesterday caused PFE’s share price to rebound sharply from the lower boundary of the blue channel towards its median, encountering little resistance when breaking through the September local barrier at $24.75.
It is possible that positive market sentiment will persist and be leveraged by bulls to extend the rally. However, the real test of their resolve might come at resistance near the summer highs around $26.00.
A more substantial obstacle might lie in the $27–27.50 area, where multiple resistances converge, including:
→ the upper boundaries of both the blue and orange channels;
→ key highs from the first half of 2025.
Nonetheless, assuming the fundamental backdrop continues to be supported by positive news on progress in cancer treatments (Pfizer is conducting large-scale developments in this area, aided by its acquisition of Seagen, a pioneer in antibody-drug conjugates, or ADCs), this could lead to an attempt to break the long-term downward trend as early as this year.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Pfizer’s Next Big Shot: COVID Levels Back on the Table?Huge Crisis or Groundbreaking Discovery?
This scenario suggests that once the running flat correction is completed — which we are very close to — the price is set to explode by at least 300% in the coming years (see red box).
Why do I think so?
• The running correction is approaching its final target zone, meaning the price should soon stop, reverse, and start pumping.
• After the correction phase comes the impulse, and we are expecting Wave 3 — the most volatile and dynamic wave of all.
• Minimum target: $108
It’s only a matter of sooner or later.
Pfizer's Weekly Supply Rejection Points to Possible TriggerPfizer Inc. recently retested a significant weekly supply zone, experiencing a rejection that suggests the market may revisit this level again. This retest could serve as a setup for a potential decline toward the daily demand area. Additionally, seasonal analysis indicates that the stock may continue its bearish trend, supporting the possibility of further downside movement. Traders should monitor these technical levels and seasonal signals for potential trading opportunities aligned with the ongoing bearish outlook.
✅ Please share your thoughts about PFE in the comments section below and HIT LIKE if you appreciate my analysis. Don't forget to FOLLOW ME; you will help us a lot with this small contribution.
The Collaborative Edge: Pfizer's Innovation Secret? Pfizer's success in the biopharmaceutical industry hinges on its internal capabilities and a strategic embrace of external collaboration. This proactive approach, spanning diverse technological frontiers, fuels innovation across its operations. From partnering with QuantumBasel and D-Wave to optimize production planning using quantum annealing, to collaborating with XtalPi to revolutionize drug discovery through AI-powered crystal structure prediction, Pfizer demonstrates the tangible benefits of cross-industry partnerships. These initiatives showcase a commitment to exploring cutting-edge technologies to enhance efficiency and accelerate the identification of promising drug candidates, ultimately improving patient outcomes and strengthening Pfizer's competitive position.
The article highlights specific examples of Pfizer's collaborative endeavors. The Pfizer Healthcare Hub in Freiburg acts as a catalyst, connecting internal needs with external innovation. The successful proof of technology in production planning using quantum annealing resulted in significant time and resource savings. Furthermore, the partnership with XtalPi has dramatically reduced the timeframe for determining the 3-D structure of potential drug molecules, enabling faster and more efficient drug screening. These collaborations exemplify Pfizer's strategic focus on leveraging specialized expertise and advanced technologies from external partners to overcome complex challenges in the pharmaceutical value chain.
Beyond these specific projects, Pfizer actively engages with the broader quantum computing landscape, recognizing its transformative potential for drug design, clinical studies, and personalized medicine. Collaborations with technology giants like IBM and fellow pharmaceutical companies underscore the industry-wide interest in harnessing the power of quantum computing. While the technology is still in its early stages, Pfizer's proactive participation in this collaborative ecosystem positions it at the forefront of future healthcare breakthroughs. This commitment to synergy, from basic research to market research, underscores a fundamental belief in the power of working together to drive meaningful advancements in the pharmaceutical industry.
PFE 1H Long Swing Conservative Trend TradeConservative Trend Trade
+ long impulse
+ SOS level
+ support level
+ 1/2 correction
+ biggest volumed Sp
Calculated affordable stop limit
1 to 2 R/R take profit before 1/2 of the Month
Expandable to 1/2 of the Year
Daily Trend:
"+ long impulse
+ neutral zone
+ close to 1/2 correction"
Monthly CounterTrend
"- short balance
+ unvolumed expanding ICE
+ volumed 2Sp-
+ weak test"
Yearly Trend
"+ long impulse
+ 1/2 correction
+ exhaustion volume?"
Will add more if corrects to 1/2 of 1H wave.
Pfizer Ltd. - Short Position AnalysisChart Overview:
The chart indicates that the stock is in a clear downtrend, following a descending channel pattern. The price is nearing a key horizontal support level (marked in black), and a breakdown below this level may present a shorting opportunity.
Trade Setup for Short Position:
1.Entry Trigger: Below ₹5,028 on a daily closing basis.
2.Targets:
Target 1: ₹4,885 (first demand zone).
Target 2: ₹4,760 (strong support and lower boundary of the descending channel).
3.Stop Loss: Above ₹5,187 (recent swing high and red-dotted resistance level).
4.Risk-Reward Ratio: Ensure a favorable ratio of at least 1:2.
Alternate Scenario:
If ₹5,028 holds as support, the stock might see a pullback toward ₹5,187, where selling pressure could resume.
Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name
during the pandemic, now faces a pivotal moment.
Activist investor Starboard Value has taken a $1 billion
stake, signaling potential changes on the horizon. But
what does this mean for Pfizer's future?
The company that swiftly developed a COVID-19 vaccine
now grapples with declining sales and a tumbling
stock price. Starboard's involvement brings both challenge and
opportunity. Will this be the catalyst for Pfizer's
renaissance or a sign of deeper troubles ahead?
Former Pfizer executives have been approached to assist
in the turnaround effort. Their potential involvement adds
an intriguing layer to this unfolding story. Could
their experience and insight be the key to
unlocking Pfizer's next chapter of success and innovation?
As the pharmaceutical landscape evolves post-pandemic, Pfizer's
response to this pressure could set industry trends.
Cost-cutting, strategic refocusing and potential leadership changes loom
large. How will these moves impact drug development,
patient care, and the broader healthcare ecosystem?
For investors, patients, and industry watchers, Pfizer's
next moves are crucial. Will the company
emerge stronger, leaner, and more innovative? Or will
it struggle to find its footing in a
rapidly changing market? The answers to these questions
could reshape the future of global healthcare.
PFIZER, targeting $50! Upside Prospect ON!PFE weekly data is conveying significant accumulation at the current price range.
Net positive volume has been increasing on a daily basis for the past few days -- in anticipation of the company's incoming price growth, long term.
The stock is currently sitting at 78.6 FIB level -- a discounted level where buyers converge.
Expect some significant bounce from the current range with initial target to $50.
Weekly higher lows on histogram has been registered. Trend shift is about to commence.
First Bubble up volume appearance in almost 2 months.
Spotted at 38.0
TAYOR
Safeguard capital always.
PFE (Y24.P3.E1). Sideways as part of wave 3 to 4Hi traders,
My thoughts on Pfizer to bottom out.
My level of interest is based on my common values for Elliott wave count based on a few assumptions. If it plans out, we will look for a long.
For now, expect a breakdown with this rising channel as the LH and LL overlap, bearish in nature.
All the best,
S.SAri
$PFE | Allocation/Buy Trade | Market Exec |Technical Confluences:
- Price is in Oversold Conditions in D1 timeframe
- Price action bouncing off 150% Fibo Extension
- Price is trying to go back above the Interest Zone to give some bullish momentum to the stock
Fundamental Confluences:
-Regardless how bad the negative rumours are ongoing about the side-effects from Pfizer; they are still considered a strong market leader in the Pharma industry
- They had a good response on a testing of their recent respiratory drug
- Value?
----
Health sector in your Portfolio will never be wrong with the global aging population.
I am putting this trade on as either into my Long-Term Portfolio or Swing trade for $PFE.
Depending on how market develops, I may decide to hold this bag and allocate more into it at the 178% Fibo Extension levels or cut my Buy position as shown.
-----
PFE - Will The Strong Downtrend Ever Be Retested? My thoughts showing how an extended bear move could result in the downward test of a previous bear trend line
I do expect however that one of the green trend lines will hodl so I have put price labels on each of those. It is more likely to continue up than to make this horrid move.
Imagine it going down to $3!






















